{Reference Type}: Journal Article
{Title}: The long and winding road towards new treatments against lymphatic filariasis and onchocerciasis.
{Author}: Risch F;Kazakov A;Specht S;Pfarr K;Fischer PU;Hoerauf A;Hübner MP;
{Journal}: Trends Parasitol
{Volume}: 40
{Issue}: 9
{Year}: 2024 Sep 8
{Factor}: 10.528
{DOI}: 10.1016/j.pt.2024.07.005
{Abstract}: Although lymphatic filariasis and onchocerciasis have been targeted for global elimination, these helminth infections are still a major public health problem across the tropics and subtropics. Despite decades of research, treatment options remain limited and drugs that completely clear the infections, and can be used on a large scale, are still unavailable. In the present review we discuss the strengths and weaknesses of currently available treatments and new ones in development. Novel candidates (corallopyronin A, DNDi-6166, emodepside, and oxfendazole) are currently moving through (pre)clinical development, while the development of two candidates (AWZ1066S and ABBV-4083/flubentylosin) was recently halted. The preclinical R&D pipeline for filarial infections continues to be limited, and recent setbacks highlight the importance of continuous drug discovery and testing.